Clinical Trials Logo

Peanut Allergy clinical trials

View clinical trials related to Peanut Allergy.

Filter by:

NCT ID: NCT01197053 Completed - Peanut Allergy Clinical Trials

Epicutaneous Immunotherapy in Peanut Allergy in Children

ARACHILD
Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study aims at showing that Epicutaneous Immunotherapy with peanut proteins is safe and efficacious for desensitizing children with peanut allergy.

NCT ID: NCT01170286 Completed - Peanut Allergy Clinical Trials

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Start date: July 2010
Phase: Phase 1
Study type: Interventional

The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.

NCT ID: NCT01074840 Completed - Peanut Allergy Clinical Trials

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

DCOIT
Start date: February 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if there is a way to treat children with peanut allergy to help lower the risk of severe allergic reactions and also cause them to lose their allergy to peanuts and to understand what happens to their immune systems when they have viral infections while on therapy. The approach we will use to treat peanut allergy in this study is a process called desensitization. We think that children with a peanut allergy receiving peanut oral immunotherapy will be able to eat more peanuts without having a reaction by the end of the study than they could eat at the beginning. We also think that we will be able to measure changes in their immune system and their immune system's response to viruses while they are on therapy.

NCT ID: NCT00949078 Completed - Food Allergy Clinical Trials

Omalizumab in the Treatment of Peanut Allergy

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.